Almirall reaches sales figures of 900 million euros in 2004
·Almirall continues to focus on research with its licence of a research programme for Parkinson’s Disease based on A2A receptor selective antagonists to Neurocrine Bioscience
·Almirall is awarded the “Prince Felipe Prize for Business Competitiveness for Large Enterprises” from the Ministry of Industry, Tourism and Trade
Barcelona, April 4th 2005.- Almirall, the first Spanish pharmaceutical multinational, has published its financial results upon the closure of fiscal year 2004.The sale of its products – at ex-factory prices – reached 900 million euros.
This 2004 figure includes total sales – through both direct sales and licensing agreements – of its products, which totalled 562 million euros in the Spanish market, an increase of 4.6% over the previous year.
For the current year, 2005, forecasts for total sales – through both direct sales and licensing agreements – are for 946 million euros.Sales in the domestic market are estimated at 570 million euros and those in the international market at 376 million euros.
Likewise, in 2004 Almirall once again confirmed its leading position in Spain, with more than 6% of the total market.
Investment in R&D during 2004 was 88 million euros. The forecast for the current fiscal year is 104 million euros. The overall estimate for R&D spending during the forthcoming five years is 500 million euros.
Agreement with Neurocrine Bioscience
During the course of 2004, Almirall has once again provided an impetus to research by licensing to Neurocrine Bioscience, a
Prince Felipe Prize
Also in the year 2004, Almirall received important recognition for its innovative efforts, as the company was awarded the Prince Felipe Prize for Business Excellence in the area of Business Competitiveness for large companies. This prize, granted each year by the Spanish Ministry of Industry, Tourism and Trade, was awarded to Almirall for its ongoing, exemplary efforts in the research and technological development of new medicines, for being a leader in its therapeutic areas, and for its investment endeavour in R&D, which has shown a spectacular increase in the years 2003 and 2004.
Almirall, a leading company committed to health in society
Almirall is a consolidated international pharmaceutical company that researches, develops and commercialises own R&D and licensed drugs with the aim of improving the health and quality of life of human beings.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, CPOD, psoriasis and rheumatoid arthritis.
Almirall will be investing 500 million euros in R&D over the next five years. This is the largest investment in this area by a Spanish pharmaceutical company. Forecasts for total sales in 2005 amount to 946 million euros.
Almirall, whose headquarters are in